{"id":1186,"date":"2016-12-08T15:19:58","date_gmt":"2016-12-08T15:19:58","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=1186"},"modified":"2017-08-21T10:33:56","modified_gmt":"2017-08-21T10:33:56","slug":"primary-care-corner-with-geoffrey-modest-md-fda-broadens-indication-for-empagliflozin-to-include-cardiovascular-protection","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/12\/08\/primary-care-corner-with-geoffrey-modest-md-fda-broadens-indication-for-empagliflozin-to-include-cardiovascular-protection\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD:  FDA broadens indication for empagliflozin to include cardiovascular protection!!!"},"content":{"rendered":"<p><strong>By Dr. Geoffrey Modest<\/strong><\/p>\n<p>The FDA just extended the indication for the diabetes drug empagliflozin (Jardiance) to include reducing cardiovascular mortality in those with diabetes and cardiovascular disease.\u00a0Their press release (see\u00a0<a href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm531517.htm\">http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm531517.htm<\/a> ) states that they looked at postmarketing data, though their original approval 2 years ago indicated that they requested\u00a05 years of post-marketing data.<\/p>\n<p>See my prior blog critiquing the original study leading to FDA approval (\u00a0<a href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/12\/21\/primary-care-corner-with-geoffrey-modest-md-empaglifozin-the-good-and-the-bad\/\">https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/12\/21\/primary-care-corner-with-geoffrey-modest-md-empaglifozin-the-good-and-the-bad\/<\/a> )<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Primary Care Corner with Geoffrey Modest MD:  FDA broadens indication for empagliflozin to include cardiovascular protection!!! [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/12\/08\/primary-care-corner-with-geoffrey-modest-md-fda-broadens-indication-for-empagliflozin-to-include-cardiovascular-protection\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-1186","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/1186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=1186"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/1186\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=1186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=1186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=1186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}